Dr. Jones received his PhD in Experimental Pathology from the University of Maryland under the guidance of Dr. Benjamin F. Trump and completed a post-doctoral fellowship with Dr. Sten Orrenius at the Karolinska Institute in Stockholm, Sweden. He joined the faculty of the University of Maryland School of Medicine in the Department of Pathology and rose to the rank of Associate Professor with tenure. His laboratory received major funding support from the American Cancer Society and the National Institutes of Health.
Dr. Jones joined Eli Lilly and Co. in 1991 as a Research Scientist in Toxicology. His nearly 28-year career included a variety of technical and administrative roles. From 2009 until his retirement at the end of 2018, Dr. Jones was responsible for providing scientific oversight and administrative leadership for the Toxicology and Pathology organization which provided the nonclinical safety support of the Lilly Research Laboratories (LRL) portfolio. These responsibilities included: scientific oversight; strategic planning, resourcing; budget; compliance; vendor management; and review and approval of key documents and reports. He served on a number of LRL committees associated with portfolio management and patient safety.
Dr. Jones has been an active member of the society of Toxicology for over 30 years. He has served on a number of committees and has presented at the annual meeting and at regional chapter meetings on numerous occasions. He was the Lilly representative to the Preclinical Safety Leadership Group (DruSafe) within the International Consortium for Innovation and Quality in Pharmaceutical Development and served on the Coordinating Committee from 2013 to 2015. He was also a founding member of the BioCelerate/TransCelerate Toxicology Data Sharing Project attempting the first sustainable cross-industry toxicology data sharing initiative using SEND data. He currently serves as the nonclinical safety representative for the Development Special Emphasis Panel supporting the NCI Experimental Therapeutics (NExT) Program. Through his accumulated experiences, Dr. Jones has developed valuable insights into the challenges and opportunities associated with the application of nonclinical safety data in human risk management.